All Stories

  1. Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia

    Article • Pathology International, December 2025, Wiley

    Dr VISHWA JEET AMATYA

  2. Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung

    Article • Cancers, November 2023, MDPI AG

    Dr VISHWA JEET AMATYA

  3. Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung

    Article • November 2023, MDPI AG

    Dr VISHWA JEET AMATYA

  4. miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV

    Article • Pathobiology, January 2023, Karger Publishers

    Dr VISHWA JEET AMATYA

  5. Intratumoral Hemorrhage After Endoscopic Third Ventriculostomy for Obstructive Hydrocephalus Caused by Brain Tumors

    Article • World Neurosurgery, February 2022, Elsevier

    Dr VISHWA JEET AMATYA

  6. Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor

    Article • Diagnostics, January 2022, MDPI AG

    Dr VISHWA JEET AMATYA

  7. Detecting non-germinomatous germ cell tumor component by arterial spin labeling perfusion-weighted MR imaging in central nervous system germ cell tumor

    Article • European Journal of Radiology, March 2021, Elsevier

    Dr VISHWA JEET AMATYA

  8. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B

    Article • World Neurosurgery, August 2020, Elsevier

    Dr VISHWA JEET AMATYA

  9. Corrigendum to “T2-FLAIR mismatch sign in dysembryoplastic neuroepithelial tumor” [Eur. J. Radiol. 126 (2020) 108924]

    Article • European Journal of Radiology, August 2020, Elsevier

    Dr VISHWA JEET AMATYA

  10. Advantage of high b value diffusion-weighted imaging for differentiation of common pediatric brain tumors in posterior fossa

    Article • European Journal of Radiology, July 2020, Elsevier

    Dr VISHWA JEET AMATYA

  11. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma

    Article • The American Journal of Surgical Pathology, June 2020, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  12. T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor

    Article • European Journal of Radiology, May 2020, Elsevier

    Dr VISHWA JEET AMATYA

  13. Inhibition of miR‑18a‑3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin

    Article • Oncology Letters, April 2020, Spandidos Publications

    Dr VISHWA JEET AMATYA

  14. Utility of dual-energy CT for predicting the vascularity of meningiomas

    Article • European Journal of Radiology, February 2020, Elsevier

    Dr VISHWA JEET AMATYA

  15. Primary and Recurrent Growing Teratoma Syndrome in Central Nervous System Nongerminomatous Germ Cell Tumors: Case Series and Review of the Literature

    Article • World Neurosurgery, February 2020, Elsevier

    Dr VISHWA JEET AMATYA

  16. Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature

    Article • Pediatric Neurosurgery, January 2020, Karger Publishers

    Dr VISHWA JEET AMATYA

  17. Retrospective immunohistological study of autopsied lungs in patients with acute exacerbation of interstitial pneumonia managed with extracorporeal membrane oxygenation

    Article • Journal of Thoracic Disease, November 2019, AME Publishing Company

    Dr VISHWA JEET AMATYA

  18. Metastatic Malignant Lymphoma Mimicking Cerebral Toxoplasmosis with the "Target Sign"

    Article • Internal Medicine, April 2019, Japanese Society of Internal Medicine

    Dr VISHWA JEET AMATYA

  19. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma

    Article • Histopathology, January 2019, Wiley

    Dr VISHWA JEET AMATYA

  20. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival

    Article • Pathobiology, January 2019, Karger Publishers

    Dr VISHWA JEET AMATYA

  21. Reply to ‘MUC4 staining in sarcomatoid carcinomas’ by Berg et al.

    Article • Modern Pathology, December 2018, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  22. miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma

    Article • Frontiers in Oncology, October 2018, Frontiers

    Dr VISHWA JEET AMATYA

  23. Perfusion Computed Tomography Parameters Are Useful for Differentiating Glioblastoma, Lymphoma, and Metastasis

    Article • World Neurosurgery, August 2018, Elsevier

    Dr VISHWA JEET AMATYA

  24. Improved differentiation between high- and low-grade gliomas by combining dual-energy CT analysis and perfusion CT

    Article • Medicine, August 2018, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  25. Proton Magnetic Resonance Spectroscopy Detection of High Lipid Levels and Low Apparent Diffusion Coefficient Is Characteristic of Germinomas

    Article • World Neurosurgery, April 2018, Elsevier

    Dr VISHWA JEET AMATYA

  26. Coexistence of gastrointestinal stromal tumor and leiomyosarcoma of the stomach presenting as a collision tumor: A case report and review of literature

    Article • Pathology International, March 2018, Wiley

    Dr VISHWA JEET AMATYA

  27. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide

    Article • Journal of Neurosurgery, March 2018, Journal of Neurosurgery Publishing Group (JNSPG)

    Taiichi Saito, Dr VISHWA JEET AMATYA

  28. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

    Article • Modern Pathology, January 2018, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  29. Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

    Article • Oncology Letters, January 2018, Spandidos Publications

    Dr VISHWA JEET AMATYA

  30. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung

    Article • Scientific Reports, January 2018, Nature

    Dr VISHWA JEET AMATYA

  31. Concurrent Schwannoma and Meningioma Arising in the Same Spinal Level: A Report of Two Cases

    Article • NMC Case Report Journal, January 2018, Japan Neurosurgical Society

    Dr VISHWA JEET AMATYA

  32. Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement

    Article • Brain Pathology, November 2017, Wiley

    Dr VISHWA JEET AMATYA, Kazuhiko Sugiyama, Sshinya Tanaka

  33. P1.02-002 Diagnostic Utility of MUC4 Expression to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma and Squamous Cell Carcinoma

    Article • Journal of Thoracic Oncology, November 2017, Elsevier

    Dr VISHWA JEET AMATYA

  34. P1.02-052 Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma

    Article • Journal of Thoracic Oncology, November 2017, Elsevier

    Dr VISHWA JEET AMATYA

  35. P2.09-008 Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma

    Article • Journal of Thoracic Oncology, November 2017, Elsevier

    Dr VISHWA JEET AMATYA

  36. RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging

    Article • Brain Tumor Pathology, October 2017, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  37. Role for loss of nuclear PTEN in a harbinger of brain metastases

    Article • Journal of Clinical Neuroscience, October 2017, Elsevier

    Dr VISHWA JEET AMATYA

  38. Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma

    Article • The American Journal of Surgical Pathology, August 2017, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  39. Sellar Atypical Teratoid/Rhabdoid Tumor (AT/RT)

    Article • The American Journal of Surgical Pathology, July 2017, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  40. Diffuse leptomeningeal glioneuronal tumor (DLGNT) mimicking Whipple’s disease: a case report and literature review

    Article • Child s Nervous System, April 2017, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  41. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator

    Article • Journal of Neurosurgery, March 2017, Journal of Neurosurgery Publishing Group (JNSPG)

    Fumiyuki Yamasaki, Dr VISHWA JEET AMATYA

  42. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

    Article • Modern Pathology, January 2017, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  43. PIM1 knockdown inhibits cell proliferation and invasion of mesothelioma cells

    Article • International Journal of Oncology, January 2017, Spandidos Publications

    Dr VISHWA JEET AMATYA

  44. 1058

    Article • Critical Care Medicine, December 2016, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  45. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma

    Article • Histopathology, November 2016, Wiley

    Dr VISHWA JEET AMATYA

  46. Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma

    Article • Pathobiology, August 2016, Karger Publishers

    Dr VISHWA JEET AMATYA

  47. Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma

    Article • International Journal of Oncology, January 2016, Spandidos Publications

    Dr VISHWA JEET AMATYA

  48. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia

    Article • Pathobiology, January 2016, Karger Publishers

    Dr VISHWA JEET AMATYA

  49. Solitary Langerhans cell histiocytosis located in the neurohypophysis with a positive titer HCG-β in the cerebrospinal fluid

    Article • Child s Nervous System, November 2015, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  50. Benign fibrous histiocytoma arising at the temporal bone of an infant—case report and review of the literature

    Article • Child s Nervous System, July 2015, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  51. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma

    Article • Journal of Neurosurgery, June 2015, Journal of Neurosurgery Publishing Group (JNSPG)

    Fumiyuki Yamasaki, Dr VISHWA JEET AMATYA, Kazuhiko Sugiyama

  52. Desmoplastic/nodular medulloblastoma associated with anhidrotic ectodermal dysplasia

    Article • International Cancer Conference Journal, February 2013, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  53. A Case of Malignant Fibrous Histiocytoma of the Petrous Bone presenting with Facial Nerve Palsy

    Article • Japanese Journal of Neurosurgery, January 2013, The Japanese Congress of Neurological Surgeons

    Dr VISHWA JEET AMATYA

  54. A Case of Papillary Glioneuronal Tumor

    Article • Japanese Journal of Neurosurgery, January 2013, The Japanese Congress of Neurological Surgeons

    Dr VISHWA JEET AMATYA

  55. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma

    Article • Oncology Reports, October 2012, Spandidos Publications

    Dr VISHWA JEET AMATYA

  56. Lymphomas and glioblastomas: Differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T

    Article • European Journal of Radiology, February 2012, Elsevier

    Dr VISHWA JEET AMATYA

  57. CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma

    Article • Clinical Cancer Research, January 2012, American Association for Cancer Research (AACR)

    Dr VISHWA JEET AMATYA

  58. Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas

    Article • European Journal of Radiology, November 2011, Elsevier

    Dr VISHWA JEET AMATYA

  59. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines

    Article • Oncology Reports, September 2011, Spandidos Publications

    Dr VISHWA JEET AMATYA

  60. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells

    Article • Histopathology, June 2010, Wiley

    Dr VISHWA JEET AMATYA

  61. Role of PROPELLER diffusion weighted imaging and apparent diffusion coefficient in the diagnosis of sellar and parasellar lesions

    Article • European Journal of Radiology, June 2010, Elsevier

    Dr VISHWA JEET AMATYA

  62. Trigeminal neuropathy from perineural spread of an amyloidoma detected by blink reflex and thin-slice magnetic resonance imaging

    Article • Muscle & Nerve, April 2010, Wiley

    Dr VISHWA JEET AMATYA

  63. Glioblastoma treated with postoperative radio-chemotherapy: Prognostic value of apparent diffusion coefficient at MR imaging

    Article • European Journal of Radiology, March 2010, Elsevier

    Dr VISHWA JEET AMATYA

  64. Accuracy of pathological diagnosis of mesothelioma cases in Japan: Clinicopathological analysis of 382 cases

    Article • Lung Cancer, November 2009, Elsevier

    Dr VISHWA JEET AMATYA

  65. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

    Article • Histopathology, July 2009, Wiley

    Dr VISHWA JEET AMATYA

  66. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

    Article • Histopathology, May 2009, Wiley

    Dr VISHWA JEET AMATYA

  67. Clinicopathological and immunohistochemical features of three pilomyxoid astrocytomas: Comparative study with 11 pilocytic astrocytomas

    Article • Pathology International, February 2009, Wiley

    Dr VISHWA JEET AMATYA

  68. Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone

    Article • Journal of Neurosurgery, February 2009, Journal of Neurosurgery Publishing Group (JNSPG)

    Dr VISHWA JEET AMATYA

  69. A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases

    Article • American Journal of Clinical Pathology, November 2008, Oxford University Press (OUP)

    Dr VISHWA JEET AMATYA

  70. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer

    Article • Cancer Science, August 2008, Wiley

    Dr VISHWA JEET AMATYA

  71. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry

    Article • Pathology International, January 2008, Wiley

    Dr VISHWA JEET AMATYA

  72. P1-151: The useful antibodies panel for differential diagnosis between peritoneal mesothelioma and ovarian carcinoma

    Article • Journal of Thoracic Oncology, August 2007, Elsevier

    Dr VISHWA JEET AMATYA

  73. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma

    Article • Pathology International, April 2007, Wiley

    Dr VISHWA JEET AMATYA

  74. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast

    Article • Pathology International, May 2006, Wiley

    Dr VISHWA JEET AMATYA

  75. TP53 promoter methylation in human gliomas

    Article • Acta Neuropathologica, July 2005, Springer Science + Business Media

    Dr VISHWA JEET AMATYA

  76. Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma

    Article • Pathology International, January 2005, Wiley

    Dr VISHWA JEET AMATYA

  77. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation

    Article • Pathology International, October 2004, Wiley

    Dr VISHWA JEET AMATYA

  78. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung

    Article • Pathology International, July 2004, Wiley

    Dr VISHWA JEET AMATYA

  79. Meningioma in mature cystic teratoma of the ovary

    Article • Pathology International, July 2004, Wiley

    Dr VISHWA JEET AMATYA

  80. Methylation of p14 ARF gene in meningiomas and its correlation to the p53 expression and mutation

    Article • Modern Pathology, April 2004, Nature

    Dr VISHWA JEET AMATYA

  81. Study of methylation status of p14/ARF gene in benign, atypical, and anaplastic meningiomas by methylation specific PCR

    Article • International Congress Series, February 2004, Elsevier

    Dr VISHWA JEET AMATYA

  82. Myxopapillary ependymoma with anaplastic features

    Article • Pathology International, October 2003, Wiley

    Dr VISHWA JEET AMATYA

  83. Case of clear cell ependymoma of medulla oblongata: Clinicopathological and immunohistochemical study with literature review

    Article • Pathology International, May 2003, Wiley

    Dr VISHWA JEET AMATYA

  84. Meningioangiomatosis Occurring in a Young Male Without Neurofibromatosis

    Article • The American Journal of Surgical Pathology, January 2002, Wolters Kluwer Health

    Dr VISHWA JEET AMATYA

  85. Heterogeneous genetic alterations in ovarian mucinous tumors: Application and usefulness of laser capture microdissection

    Article • Human Pathology, November 2001, Elsevier

    Dr VISHWA JEET AMATYA

  86. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas

    Article • Human Pathology, September 2001, Elsevier

    Dr VISHWA JEET AMATYA

  87. Idiopathic granulomatous meningoencephalitis presenting as an intracranial tumor

    Article • Pathology International, December 1999, Wiley

    Dr VISHWA JEET AMATYA